Romidepsin was one of the early HDAC inhibitors studied in a multicentre phase 2 study 76 in relapsed AML and was seen to preferentially induce differentiation in core‐binding factor AML cases. This evidence concerns the gene HDAC9 and acute myeloid leukemia.